Results from a randomized, double-blind trial in diabetes-free adults living with obesity and high cardiovascular disease risk showed that liraglutide was associated with a reduction in both muscle ...

In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

If you’re looking into weight loss drugs, liraglutide has no doubt popped up. It’s a diabetes and weight loss medication sold under the brand names Victoza and Saxenda. Read on for everything you need ...

SAN DIEGO -- A 1-mg dose of semaglutide (Wegovy) weekly was better at maintaining weight than 3-mg liraglutide (Saxenda) daily for patients who put on pounds after bariatric surgery, a retrospective ...

An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed ...

Liraglutide is an analog with 97% homology to human glucagon-like peptide (GLP-1) and acts as a GLP-1 receptor agonist. Several large, randomized, multicenter phase 3 trials evaluated the efficacy and ...

New trial shows liraglutide helps reduce BMI in children aged 6 to 12 with obesity, but side effects prompt further study Study: Liraglutide for Children 6 to <12 Years of Age with Obesity — A ...

To investigate the effects of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor activator, on body weight and waist circumference in Chinese overweight and obese type 2 diabetic patients. This ...

The addition of liraglutide, a glucagon-like peptide-1 receptor agonist, to metformin with or without basal insulin, improves glycemic control in children and adolescents with type 2 diabetes. The ...

Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 ...

Share on Pinterest Can a GLP-1 drug help protect against cognitive decline? Early trials say ‘yes.’ Image credit: Halfpoint Images/Getty Images. Over the last year, the use of and interest in glucagon ...

KELOWNA, BC / ACCESS Newswire / February 20, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it ...